The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,796.00
Bid: 1,788.00
Ask: 1,796.00
Change: 0.00 (0.00%)
Spread: 8.00 (0.447%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,796.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genus Chief Executive Transition

25 Mar 2019 07:00

RNS Number : 8056T
Genus PLC
25 March 2019
 

For Immediate Release 25 March 2019

 

Genus plc('Genus', or the 'Company')

Genus Chief Executive Transition

Genus plc (LSE: GNS), a leading global animal genetics company, announces that Karim Bitar, Chief Executive Officer, will be stepping down from the Board from 16 September 2019. Karim will be taking the Chief Executive Officer position at ConvaTec Group Plc from 30 September 2019. Karim has committed to remain with Genus and continue in his role until 16 September, to achieve an orderly succession and transition process, while continuing to drive business performance.

"During Karim's eight years at Genus as Chief Executive, the Company has been transformed into a world-leading animal genetics company, truly fulfilling its vision to pioneer animal genetic improvement to help nourish the world. He has led the Company's transformation and is leaving the Company in excellent shape with a world-class leadership team, world-class genetics and innovative technology platforms to enable us to pursue many exciting global opportunities," said Bob Lawson Chair of Genus. "His legacy is the creation of an outstanding global team that will sustain the Company's growth, while serving customers with an unparalleled range of products and services. Karim has provided the Company with many years of strong leadership, and the Board and I remain excited by the Company's future prospects. On behalf of the Board and all at Genus, I wish Karim well for the future and thank him for his considerable contribution during his time with the Company."

Karim Bitar said "It has been a great privilege to lead such a talented group of people and develop a leading global agricultural biotechnology company focused on animal genetics. Genus is in a very strong strategic and financial position, with significant growth prospects and I will miss the team tremendously when I eventually leave in September."

The Board has commenced a search to identify his successor and a further announcement will be made in due course. 

For further information please contact:

Genus

Tel: +44(0)1256 345970

Bob Lawson, Chair

 

Stephen Wilson, Group Finance Director

 

Buchanan

Tel: +44(0)207 466 5000

Charles Ryland /Chris Lane/Sophie Wills

 

This announcement is available on the Genus website www.genusplc.com

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Regulatory Notes

Details of Karim Bitar's terms of departure are still to be finalised. Any such terms will be consistent with the Company's approved Directors Remuneration Policy. Details of any payments to be made to Karim will be posted on the Company's website, in accordance with section 430(2B) Companies Act 2006. This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014. The person responsible for making this announcement on behalf of the Group is Dan Hartley (General Counsel and Company Secretary).

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUMGWUPBGBC
Date   Source Headline
1st Feb 20161:22 pmRNSBlocklisting Interim Review
4th Jan 20165:40 pmRNSTotal Voting Rights
11th Dec 20153:14 pmRNSDirector/PDMR Shareholding
9th Dec 20154:30 pmRNSDirector/PDMR Shareholding
8th Dec 20157:00 amRNSTackles major pig disease with breakthrough tech
1st Dec 20154:54 pmRNSHolding(s) in Company
1st Dec 20154:46 pmRNSTotal Voting Rights
19th Nov 20152:52 pmRNSResult of AGM
19th Nov 20157:00 amRNSAGM - TRADING UPDATE
2nd Nov 20153:04 pmRNSTotal Voting Rights
22nd Oct 20155:48 pmRNSHolding(s) in Company
21st Oct 20156:10 pmRNSDirector/PDMR Shareholding
15th Oct 201512:46 pmRNSAnnual Report and Notice of AGM
1st Oct 20153:00 pmRNSTotal Voting Rights
15th Sep 201511:00 amRNSDirector/PDMR Shareholding
8th Sep 20157:00 amRNSPreliminary Results
3rd Aug 20152:00 pmRNSBlocklisting Interim Review
30th Jun 20152:00 pmRNSTotal Voting Rights
29th Jun 20152:00 pmRNSChange of Registered Office
29th May 20152:00 pmRNSTotal Voting Rights
12th May 20157:00 amRNSCapital Markets Event and Trading Update
11th May 20152:00 pmRNSHolding(s) in Company
7th May 20152:21 pmRNSHolding(s) in Company
30th Apr 20152:00 pmRNSTotal Voting Rights
14th Apr 20152:00 pmRNSDirector/PDMR Shareholding
13th Apr 20155:06 pmRNSHolding(s) in Company
1st Apr 20157:00 amRNSCompletion of acquisition
31st Mar 20154:04 pmRNSTotal Voting Rights
19th Mar 20155:46 pmRNSDirector/PDMR Shareholding
12th Mar 20152:09 pmRNSDirector/PDMR Shareholding
9th Mar 20151:24 pmRNSDirector Declaration
27th Feb 20152:00 pmRNSTotal Voting Rights
24th Feb 201511:00 amRNSHolding(s) in Company
24th Feb 20157:00 amRNSInterim Results
16th Feb 20157:00 amRNSAcquisition of 51% of In Vitro Brasil
2nd Feb 20151:22 pmRNSBlock Listing Six Monthly Return
31st Dec 201412:01 pmRNSTotal Voting Rights
12th Dec 201410:44 amRNSDirector/PDMR Shareholding
1st Dec 20144:36 pmRNSTotal Voting Rights
21st Nov 20144:03 pmRNSDirector/PDMR Shareholding
14th Nov 20143:42 pmRNSResult of AGM
14th Nov 20147:00 amRNSTrading Update
31st Oct 201412:20 pmRNSTotal Voting Rights
22nd Oct 20149:29 amRNSDirector/PDMR Shareholding
10th Oct 20145:58 pmRNSHolding(s) in Company
8th Oct 20143:47 pmRNSAnnual Report and Annual General Meeting
3rd Sep 20147:00 amRNSPreliminary Results
3rd Sep 20147:00 amRNSPorcine Multiplication Agreement in China
29th Aug 20143:08 pmRNSTotal Voting Rights
1st Aug 20142:00 pmRNSBlock Listing 6 Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.